Global Gamma Delta T Cell Cancer Therapy Opportunity & Clinical Trials Insights 2026: ADI-001, LAVA-051, INB-200, TCB002, INB-100, ACE1831 & GDX012

DUBLIN, May 24, 2021 /PRNewswire/ -- The "Global Gamma Delta T Cell Cancer Therapy Opportunity & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.

Over the past few years, the idea of immunotherapy of ability to manipulate immune cells in targeting tumor cells is gaining momentum in field of cancer therapeutics. Since then scientists have developed a wide range of potential candidates which has shown encouraging results in the management of cancer.

The recent clinical success of chimeric antigen receptor in the management of hematological malignancies has clearly led to the explosion in the field of adoptive cell therapy for cancer. Researchers are currently putting efforts for the translation of this exciting technology in solid tumors and the development of allogeneic off the shelf therapies.

With the progress in biotechnology researchers were able to identify gamma delta T cells which have potential role in cancer immunosurveillance and have the potential to overcome the challenges in adoptive cell therapy. The cells have both innate and adaptive like properties, thus bridging between the adaptive and innate immunity. Furthermore, these subsets of cells produce different cytokines, chemokine and growth factors which help in generating immune response against the tumor cells.

Since their identification, gamma delta T cells are attractive candidates for the adoptive T cell therapy due to their unique biology and favorable characteristics in the management of cancer. The unique ability of targeting cells in major histocompatibility complex independent manner and recognizing a broader range of antigens has gained a lot of interest by the researchers. As of now, there are no approved gamma delta T therapies but a pool is present in clinical trials. Majority of the candidates belongs to early phase clinical trial which will require about 5-7 years to enter the market.

The encouraging response of the gamma delta T cell therapy in the management of cancer has surged the researchers for the exploiting the role of gamma delta T cells in other diseases also. A number of preclinical studies have been initiated by researchers to identify their role in diabetes, infectious and autoimmune diseases. As per report, it is expected that global gamma T cell therapy will witness huge growth rate in coming years and the market will be flourished with various potential candidates in management of wide range of diseases.

Despite several restraining factors in the growth of market including low physical frequency, high cost of development and stringent regulatory guidelines the overall market will follow a trajectory path. This is mainly due to the rising partnerships and collaborations among the pharmaceutical companies which increases the investment to carry out research and development activities.

The major key players operating in the market are Acopedia, Takeda Pharma, TC Biopharma and Adapate Therapeutics which have robust clinical pipeline of gamma delta T cells candidates.

In coming years, the subsequent rise in the prevalence of cancer and the rates at which conventional therapies are failing will possess unmet need for the development of novel therapies which will drive the gamma delta T cell therapy market. Moreover, the exploitation of the therapy in management of other diseases will also propel the growth of marker.

In addition to this, it is analyzed that North America will hold the top position in the global market due to rising geriatric population and increase government initiatives to promote novel therapies. In the forecast period, Europe and Asia-Pacific will also emerge as a potential market due to increase in awareness among the population of the region.

Report Highlights

• Commercialization Market Potential After Market Launch: > USD 4 Billion
• Insight on Key Drugs In Research & Development
• Global Gamma Delta T Cell Cancer Therapy Clinical Trials Insight
• Gamma Delta T Cell Cancer Therapy In clinical Trials: > 15 Therapies
• Gamma Delta T Cell Cancer Therapy Market Opportunity By Cancer Type
• Adopted Approaches for Gamma Delta T Cell Therapy

Key Topics Covered:

1. Introduction to Gamma Delta T Cell Therapy
1.1 Emerging Role of T Cell Based Immunotherapies
1.2 Overview to Gamma Delta T Cell Therapy

2. Gamma Delta T Cell Therapy Vs. Conventional Therapies
2.1 Gamma Delta T Cell Therapy Vs. CAR T Cell Therapy
2.2 Gamma Delta T Cell Therapy Vs. Tumor Infiltrating Lymphocyte Therapy
2.3 Gamma Delta T Cell Therapy Vs. Immune Checkpoint Inhibitors
2.4 Gamma Delta T Cell Therapy Vs. Monoclonal Antibodies
2.5 Gamma Delta T Cell Therapy Vs. Others

3. Role of Gamma Delta T Cells in Cancer
3.1 Gamma Delta T Cells in Cancer Progression
3.2 Anti Tumor Activity of Gamma Delta T Cells

4. Adopted Approaches for Gamma Delta T Cell Therapy
4.1 Gamma Delta T Cell as Bispecific Antibodies
4.2 CAR Gamma Delta T Cells

5. Gamma Delta T Cell Therapy: Key Drugs In Research & Development
5.1 ADI-001
5.2 LAVA-051
5.3 INB-200
5.4 TCB002
5.5 INB-100
5.6 ACE1831
5.7 GDX012

6. Global Gamma Delta T Cell Cancer Therapy Clinical Pipeline Overview
6.1 By Country
6.2 By Company
6.3 By Indication
6.4 By Phase

7. Global Gamma Delta T Cell Cancer Therapy Clinical Trials Insight
7.1 Research
7.2 Preclinical
7.3 Phase-I
7.4 Phase-II/III

8. Gamma Delta T Cell Therapy in Leukemia
8.1 Role of Gamma Delta T Cells in Leukemia
8.2 Ongoing Clinical Research in Acute Leukemia
8.3 Clinical Trials in Chronic Lymphocytic Leukemia
8.4 Future Market Opportunity of Gamma Delta T Cells in Leukemia

9. Gamma Delta T Cell Therapy in Lung Cancer
9.1 Overview
9.2 Ongoing Research & Development
9.3 Future Market Opportunity of Gamma Delta T Cell Therapy in Lung Cancer

10. Gamma Delta T Cells in Breast Cancer
10.1 Overview
10.2 Ongoing Research & Development in Breast Cancer
10.3 Future Market Opportunity of Gamma Delta T Cell Therapy in Breast Cancer

11. Gamma Delta T Cells in Colorectal Cancer
11.1 Function of Gamma Delta T Cells in Colorectal Cancer
11.2 Ongoing Clinical Trials in Colorectal Cancer
11.3 Future Market Potential of Gamma Delta T Cell Therapy in Colorectal Cancer

12. Gamma Delta T Cells in Pancreatic Cancer
12.1 Overview
12.2 Ongoing Research & Development in Pancreatic Cancer
12.3 Future Market Potential of Gamma Delta Therapy in Pancreatic Cancer

13. Current Clinical Research in Other Cancers
13.1 Ongoing Clinical Trials in Neuroblastoma
13.2 Ongoing Clinical Trials in Glioblastoma
13.3 Ongoing Research & Development in Head & Neck Cancer

14. Gamma Delta T Cell Therapy Market Overview
14.1 Current Market Scenario
14.2 Market Potential of Gamma Delta T Cell Therapy Market

15. Gamma Delta T Cell Therapy Market Dynamics
15.1 Gamma Delta T Cell Therapy Market: Favorable Parameters
15.2 Gamma Delta T Cell Therapy Market: Challenges

16. Gamma Delta T Cell Therapy Future Prospects

17. Competitive Landscape
17.1 Acepodia
17.2 Adaptate Therapeutics
17.3 Adicet
17.4 Cytomed Therapeutics
17.5 Gadeta
17.6 GammaDelta Therapeutics
17.7 IN8bio
17.8 Kiromic Biopharma
17.9 Lava Therapeutics
17.10 Takeda Pharmaceuticals
17.11 TC Biopharm

For more information about this report visit https://www.researchandmarkets.com/r/gu3rfb

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets